Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Carclo Plc LSE:CAR London Ordinary Share GB0001751915 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.95 7.6% 13.45 316,499 16:35:24
Bid Price Offer Price High Price Low Price Open Price
12.95 13.95 13.85 13.25 13.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 110.51 -0.55 -15.50 10
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:15 O 20 13.95 GBX

Carclo (CAR) Latest News

More Carclo News
Carclo Investors    Carclo Takeover Rumours

Carclo (CAR) Discussions and Chat

Carclo (CAR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-12-04 16:29:1513.95202.79O
2020-12-04 16:29:1512.95101.30O
2020-12-04 16:29:1512.9570.91O
2020-12-04 16:12:1613.153,025397.79O
2020-12-04 16:07:1113.151,000131.50O
View all Carclo trades in real-time

Carclo (CAR) Top Chat Posts

DateSubject
05/12/2020
08:20
Carclo Daily Update: Carclo Plc is listed in the Chemicals sector of the London Stock Exchange with ticker CAR. The last closing price for Carclo was 12.50p.
Carclo Plc has a 4 week average price of 12.45p and a 12 week average price of 12.45p.
The 1 year high share price is 26.50p while the 1 year low share price is currently 3.10p.
There are currently 73,286,918 shares in issue and the average daily traded volume is 1,110,652 shares. The market capitalisation of Carclo Plc is £9,857,090.47.
03/12/2020
10:34
2magpies: volatility probably down to low volume also rather too much chopping and changing at board level. cooks leaving and changing around in the ktchen is bound to affect the cooking, Mr Market probably thinks. pension deficit is a bit of an albatross hanging around CAR's neck: hopefully it will free itself and fly off one day!! bottom line: CAR actually makes something that's useful (even vital). And that has value. imo
27/11/2020
14:30
laurence llewelyn binliner: Share price settling around 15p as investors digest the H1 trading update to 31.09.2020 What we know is the exceptional costs are are largely or wholly worked through, there are new orders for tooling which will translate into sales of parts, hopefully in H2 as production of those parts are delivered and paid for.. A YoY H1 reduction of just 11% on revenue in a CV19 pandemic where for most of Q1 everything was shut, nobody knew how to respond and when they were allowed to do it, business only partly normalised in Q2, with H2 looking much better and expected added sales/deliveries from new orders being realised.. Net debt is reduced and under new leadership Aero will be refocused onto other revenue adding project work.. Overall I would say well done in surviving the Wipac separation firstly, then well done on surviving an H1 pandemic business environment, recovery will be slow and steady to repair the balance sheet and it does not happen in a couple of months, but we have started and will be in a lot better shape in 2 or 3 years from now when we revisit banking needs.. Dividends looks a way off though... :o)
27/11/2020
14:13
rivaldo: Agreed ansc - Tradertrev is spot on. CAR remains a decent bet to me too over time. I did expect a better overall H1 result, especially as aerospace wasn't as bad as I'd expected, but conversely CTP whilst doing OK wasn't as good as I'd hoped. Given that CAR feel confident enough today to state that H2 should be "marginally stronger", I suspect the actual results may be better than that. Especially with the new COVID-19 tooling contracts and the stated higher CTP product sales kicking in. The pension situation will of course fluctuate but should diminish as time goes on, whilst net debt is steadily reducing. I completely agree that CAR's investor relations are non-existent - especially as at this mere £11m m/cap they should be engaging with PIs as much as if not more than institutions. Anyway, it's encouraging that CAR can conclude today: "Demand for CTP products in the medical diagnostics sector is increasing as a result of the pandemic and we hope to secure further new contract awards over the coming months."
27/11/2020
13:08
topnotch: Seems I'm not the only one - lifted form LSE board... "As a shareholder of CAR.L I would like to comment on this company's PR performance. Apart from fundamental or technical aspects I always assess the ability of a company to effectively communicate with the broader investment community. Unfortunately Carclo is a disaster in this field. A site not frequently updated with product or other news, not a tweet since Nov.29, 2017, no use of other social media, no information or link about Carclo Safetywear (https://carclo-safetywear.com/contact/, I am not quite sure if this company is part of Carclo plc). There is no price information on Investors' section and the RNS information is provided upon registration. I hope things will get better now that the business stabilizes (I express no opinion because I believe it is hard to have an opinion on this company)." It's almost as if the company doesn't care about the stakeholders
18/11/2020
16:55
laurence llewelyn binliner: #Wigwammer, frustrating is it not, but best to keep focused on the progress of the company rather than the share price currently, the volume is so thin it must be a PITA to try and make a market on the share.. Only a week until news for H1, and some post period comment for Oct/Nov.. :o)
16/10/2020
15:22
garth: I know that 2027 is along way out, but I was interested to read that by that point medical segment is expected to overtake automotive segment in injection moulding (2-shot) For Carclo, the Bangalore facility plays a part in that. And re my earlier question on capital expenditure, I guess much of that is already done. hTTps://www.carclo-ctp.co.uk/media-centre/press-releases/2020/10-07-2020 Of course, what we know about the global pandemic, test kits, inhalers - all could be expected to accelerate that and increase the rate of market growth above that suggested below. "The global 2-shot injection molding market is projected to grow at a CAGR of nearly 7% between 2019 and 2027. Rising demand for high precision parts in automotive & medical industry coupled with growing use of recycle plastics is likely to drive 2-shot injection molding market during the forecast period." …… "In terms of application, automotive applications was the largest segment of the 2-shot injection molding market, accounting for more than 25% share in 2018. However, the medical segment was projected to overtake the automotive segment by 2027." hTTps://www.openpr.com/news/2160070/key-developments-in-global-2-shot-injection-molding-market
11/9/2020
13:24
1gw: Well I did sell out at around a 50% loss in early 2014, but then I seem to have had second thoughts and bought 1/2 of them back less than 1 month later - and have held some ever since. I've nearly always been able to see some sort of upside. In fact I think the only time I really felt there wasn't much hope was fairly recently when Covid disruption looked like it might be the final nail in the coffin for them. By that time with the share price down very low (vs my average purchase price) it seemed too late to sell, although I did sell some at 7.5p as recently as 8th August after the price had recovered to 10p and then seemed to be falling away again. Luckily I sold a relatively small proportion.
04/9/2020
15:25
garth: FOR IMMEDIATE RELEASE 2 Jul 2018 Response to announcement from Consort Medical plc Carclo plc ("Carclo" or the "Company") notes today's announcement by Consort Medical plc ("Consort") and confirms that it received a highly preliminary indicative non-binding all paper proposal for the Company from Consort on 29 May 2018 (the "Proposal"). The Proposal valued each Carclo share at 116 pence to be satisfied in new Consort shares. .... Lots of water under the bridge since then. But... G.
21/8/2020
08:42
rivaldo: Talking of the opportunity for CAR in COVID-19 - here's news of CAR producing face shields, which I don't think has been posted before? Https://www.carclo-ctp.co.uk/media-centre/press-releases/2020/27-07-2020 "Carclo Safetywear Announces Launch of Face Shield for Retail 27 July 2020 London - Rob Stutzman, Carclo Technical Plastics Divisional Chief Executive, is pleased to announce the launch of Carclo’s innovative Face Shield - supporting a range of local and international commercial ventures getting back to work during the COVID-19 crisis. "Our unique Face Shield system has a replacement visor to improve the overall cost efficiency of the solution. It also has a number of unique features including, foam comfort band, a fully adjustable over-head support cradle, and anti-fog visors with the ability to pivot the visor up and down without removing the headwear." The project has been developed through Carclo’s Czech business, based in Brno, with support from its India subsidiary in Bangalore. Our team utilised rapid 3D printing technology to test and develop the design, followed by the development of fully hardened injection mould tools to help deliver the project in accelerated timescales. Sales and Marketing has been led by Carclo’s direct distribution business based out of Aylesbury in the UK, with its US and China plants taking an active role in promoting the project to customers in those regions. Carclo Safetywear Announces Launch of Face Shield for Retail Stutzman further commented that "the project has been an ideal platform to support local economies following the unprecedented global issues surrounding COVID-19. It has also highlighted the company’s global capabilities to complete the project from concept to stock in an accelerated timeline. This is an excellent example of how Carclo’s businesses came together to offer an important safety product in record time." To learn more about the applications the Face Shield can serve or to purchase please visit www.carclo-safetywear.com. For more information or volume inquiries, please contact Andrew Green, Andrew.green@Carclo-safetywear.com."
17/8/2020
10:18
garth: Wig, I have been invested in CAR on and off - more on than off - since early 2003. I understand the potential. I have also carried an ongoing awareness of the risks posed by the debt and the pension deficit. I understand that the the support of banks was a key aspect this morning - its key because of the debt! They have to service the debt and they have to service the pension deficit. And they have to turn what should be a cracking British business into a profitable one again. I do not disagree with anyone that robust is positive. But I hold to my contention that the CURRENT state of that demand is less than would be implied by use of the word strong. And it DOES matter - because those words get pinned to varying levels of £/% Magpie - as a long term holder I disagree that "robust" in this context can mean "(i.e able to withstand future shocks, from multiple directions)" I do not believe that recent trading in combinations with the level of debt and pension deficit leave CAR well placed to deal with future shocks from multiple directions. Give it a couple of years of cost reduction and realignment and sustained evidence of a corner turned, then maybe. This morning was positive and makes CAR investible, IMO. But it remains very risky. But with that risk comes the opportunity to enjoy many multiples of increase in investment value - providing they can execute. I am a long term holder and have what is for me a decent sum invested. And I was buying at 5/6p. Best wishes one and all. And thank you for the continued high quality of thought, research and exchange - even when in shades of disagreement. G.
Carclo share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
CAR
Carclo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201205 09:29:21